Previsioni

Il prezzo obiettivo medio degli analisti è 69,48 € (+27,70%). La mediana è 75,95 € (+39,59%).

Acquista	7
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

MBX Biosciences hits record high at $69.50

MBX Biosciences stock rose to an all‑time high of $69.50 after a one‑year gain of 414% and a 104% increase year‑to‑date. Six analysts recently raised their earnings estimates, while a fair‑value analysis rates the stock as slightly overvalued. Quarterly results are due in two days; the company recently underwent leadership changes with Steve Hoerter as new chairman and CEO and John Smither named permanent CFO. Phase‑2 data for canvuparatid showed a 57% response rate after one year, but the stock initially fell on the news; Stifel raised its price target to $56 and maintained a "Buy" rating after positive MBX‑4291 data. » Altro su de.investing.com
MBX Biosciences reaches new all-time high at $66.66

MBX Biosciences stock rose to a new all-time high of $66.66 and is up 336.31% year-to-date; it currently trades at $65.30, about 1% below the 52-week high. InvestingPro values the stock slightly above its fair value. The company announced leadership changes: Steve Hoerter will be chairman and CEO, John Smither permanent CFO, and co-founder Kent Hawryluk resigned. MBX released Phase 2 data on canvuparatid showing annual response rates of 57%, but the stock later fell; Stifel raised its price target to $56 and maintained a buy rating after positive interim data on MBX-4291. » Altro su de.investing.com
MBX Biosciences: CEO Kent Hawryluk resigns, Steve Hoerter named chairman and CEO

MBX Biosciences shares fell about 8.3% in after-hours trading following the announcement of the leadership change. Steve Hoerter was appointed chairman and chief executive officer effective immediately; Kent Hawryluk resigned as president, CEO and board member. John Smither was promoted from interim to permanent chief financial officer. MBX reaffirmed targets for H2 2026, including a Phase 3 start with Canvuparatid, nomination of a triple GLP-1/GIP/GCGR agonist, and 12-week data for MBX 4291. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, MBX Biosciences ha registrato ricavi pari a 0 € e un utile netto di -32,5 Mln €

(EUR)	giu 2026	YoY
Ricavi	0	-
Utile lordo	0	-
Utile netto	-32,5 Mln	97,36%
EBITDA	-35,79 Mln	118,04%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	2,73 Mld €
Numero di azioni	47,6 Mln
Massimo/minimo a 52 settimane	62,70 € - 8,31 €
Dividendi	No
Beta	0,10
Rapporto P/E	-27,66
Rapporto PEG	4,74
Rapporto P/B	7,73
Rapporto P/S	0,00

Profilo aziendale

MBX Biosciences, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung und Entwicklung von Präzisionspeptidtherapien für die Behandlung von endokrinen und metabolischen Störungen konzentriert. Der führende Produktkandidat ist MBX 2109, ein Peptid-Prodrug des Parathormons, das sich in einer klinischen Phase-2-Studie befindet und als potenzielle langwirksame Hormonersatztherapie für die Behandlung von chronischem Hypoparathyreoidismus entwickelt wird. Das Unternehmen entwickelt auch MBX 1416, einen lang wirkenden Glucagon-like Peptide-1 (GLP-1)-Rezeptor-Antagonisten, der sich in einer klinischen Phase-1-Studie befindet und als potenzielle Therapie für die postbariatrische Hypoglykämie, eine chronische Komplikation nach bariatrischen Operationen, entwickelt wurde. Darüber hinaus entwickelt das Unternehmen MBX 4291, einen führenden Produktkandidaten zur Behandlung von Fettleibigkeit, der sich in Studien zur Zulassung eines neuen Medikaments befindet und als lang wirksamer und hochpotenter GLP-1- und glukoseabhängiger insulinotroper Polypeptid-Rezeptor-Koagonist zur Behandlung von Fettleibigkeit und Komorbiditäten konzipiert ist. Das Unternehmen wurde im Jahr 2018 gegründet und hat seinen Sitz in Carmel, Indiana.